Showing results (361-370 of 435) with videos related to
Sort By:
Pageof 44
International Journal of Cancer|July 16, 2021
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancerKatie Watts, Christopher Wills, Ayman Madi, et al.Diabetes Technology & Therapeutics|January 9, 2024
Comparator Data Characteristics and Testing Procedures for the Clinical Performance Evaluation of Continuous Glucose Monitoring SystemsManuel Eichenlaub, Stefan Pleus, Martina Rothenbühler, et al.European Journal of Cancer (Oxford, England : 1990)|August 19, 2008
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1)Ivan Popov, Alfredo Carrato, Alberto Sobrero, et al.Journal of Diabetes Science and Technology|March 7, 2026
Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus ReportGuillermo E Umpierrez, Viral N Shah, Veronica Brady, et al.British Journal of Cancer|August 8, 2019
Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stageMark A Glaire, Enric Domingo, Anita Sveen, et al.Oncogenesis|February 21, 2019
An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistanceNingning Li, Roya Babaei-Jadidi, Federica Lorenzi, et al.British Journal of Cancer|September 25, 2019
Correction: Tumour-infiltrating CD8+ lymphocytes and colorectal cancer recurrence by tumour and nodal stageMark A Glaire, Enric Domingo, Anita Sveen, et al.ESMO Open|November 21, 2020
Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancerChristian H Bergsland, Jarle Bruun, Marianne G Guren, et al.Cancer Research|July 18, 2023
GTP Cyclohydrolase Drives Breast Cancer Development and Promotes EMT in an Enzyme-Independent MannerZijing Wang, Nan Zhang, Miao Zhang, et al.BMC Cancer|July 24, 2021
A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphomaStephen W Booth, Toby A Eyre, John Whittaker, et al.Pageof 44